Pillar® ONCO/Reveal™ Lung and Colon Cancer Panel
The ONCO/Reveal Lung and Colon Cancer Panel is a robust NGS assay that interrogates 22 genes of interest across lung and colon cancer samples. The panel uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library preparation chemistry for efficient single-tube target enrichment.
Panel highlights
Requires as little as 2.5ng of input DNA
Targets more than 1,800 hotspots
From sample to library in as little as 5 hours (2hrs hands on)
Robust to FFPE degradation
For research use only. Not for use in diagnostic procedures.
Panel targets
| AKT1 | EGFR | FGFR2 | NOTCH1 | STK11 |
| ALK | ERBB2 | FGFR3 | NRAS | TP53 |
| BRAF | ERBB4 | KRAS | PIK3CA | |
| CTNNB1 | FBXW7 | MAP2K1 | PTEN | |
| DDR2 | FGFR1 | MET | SMAD4 |
Panel specifications
| Enrichment chemistry | Multiplex PCR using tiled amplicons |
| Number of pools | 1 pool |
| Number of genes/amplicons | 22/103 |
| Number of targets | >1,800 hotspots, 11kb total size |
| Variant types | SNVs, indels |
| Average amplicon size | 147bp |
| Recommended DNA input range | 2.5ng to 80ng |
| Sample types | DNA from tissue or blood; cfDNA; FFPE |
| Mapping rate | 97.4% ± 2.5% |
| % on-target aligned reads | 96.8% ± 1.3% |
| Coverage uniformity (% targets with >0.2X mean coverage) | 99.8% ± 0.7% |
| Total assay time (from DNA to sequencer) | <8 hours |
| Sequencing platforms | Illumina® and MGISEQ™; assay is coming soon for the Ion Torrent™ platform |
See the data
Sensitive variant detection
The ONCO/Reveal Lung and Colon Cancer Panel is highly precise even with low DNA inputs, demonstrating high concordance (R2 >99%) between input amounts across a wide range of variant allele frequencies.
Assays and analyses were performed at Dartmouth Hitchcock Medical Center and presented at AMP 2016.
Robust variant detection
The ONCO/Reveal Lung and Colon Cancer Panel is accurate, precise, repeatable and sensitive to near the limit of detection regardless of FFPE quality.
In the figure to the right, formalin-compromised
reference standards (Horizon Discovery) were
evaluated using the ONCO/Reveal Lung and Colon Cancer Panel, which demonstrated accurate results from degraded samples.
N=10; error bars=standard deviation
